2型糖尿病和糖尿病前期患者的禁食胰岛素水平和mfERG隐性时间之间的关系
Jennyffer D Smith1, Rachel Redfern2, Liam Burhans2
1University of Houston College of Optometry, Houston, TX, USA. jsmith41@central.uh.edu.
Documenta ophthalmologica. Advances in ophthalmology
|February 19, 2025
概括
血中的胰岛素降低与2型糖尿病 (T2DM) 或糖尿病前期的禁食患者的视网膜功能延迟 (P1隐性时间) 有关. 这表明胰岛素缺乏可能会在视网膜病变发生之前就会损害视力.
科学领域:
- 眼科医生 眼科 眼科
- 内分泌学 在内分泌学.
- 糖尿病学 糖尿病学
背景情况:
- 已知2型糖尿病 (T2DM) 可以改变多焦点电网膜学 (mfERG) 参数,特别是延迟P1隐性时间 (IT),甚至在视网膜病变明显之前.
- 这种延迟通常归因于高血糖引起的视网膜细胞损伤.
- 然而,在糖尿病前期和T2DM患者中,改变胰岛素水平并未通过mFERG对视网膜功能产生影响.
研究的目的:
- 为了研究血液中的胰岛素水平和mfERG参数在有和没有T2DM和糖尿病前期的个体之间的关系.
- 为了探索是否胰岛素水平,独立于高血糖,影响视网膜功能,根据mfERG测量.
主要方法:
- 一项横截面研究包括66名受试者,根据HbA1c分类为对照组 (<5.7%),糖尿病前期 (5.7-6.4%) 和T2DM (>6.4%或已诊断).
- 评估了空腹血糖,空腹血胰岛素 (ELISA) 和mFERG (103个六边形,4分钟的m序列).
- 用ANOVA和多变量回归分析数据,控制年龄,T2DM持续时间和血糖.
主要成果:
- 在所有受试者中,在空腹血糖和mFERG P1 IT之间发现了显著的正相关性 (P < 0.002).
- 在控制共变量后,观察到平均mfERG IT和空腹血液胰岛素度 (P = 0.035) 之间存在负相关性.
- 与对照组和糖尿病前期组相比,T2DM患者的mfERG IT显著长 (P = 0.008),但对照组和糖尿病前期组之间没有发现差异.
结论:
- 血中的胰岛素水平降低与夜间禁食条件下的延迟mFERG P1 IT相关,这表明胰岛素缺乏可能会损害视网膜功能.
- 这些发现凸显了胰岛素在保持视网膜健康方面的潜在作用,独立于直接的高血糖影响.
- 建议进行进一步的研究,以在标准化的食后条件下探索这些关联,例如在口服葡萄糖耐受性测试期间.
更多相关视频
08:30Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
Published on: March 15, 2018
14.1K
08:06Assessment of the Metabolic Effects of Isocaloric 2:1 Intermittent Fasting in Mice
Published on: November 27, 2019
8.8K
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Insulin: Dosing Regimen and Adverse Effects
139
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
139
Diabetes: Symptoms, Diagnosis, and Complications
498
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
498
Dipeptidyl Peptidase 4 Inhibitors
164
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
164
